Altered Expression of RANKL/OPG after Alendronate Administration in the Developing Teeth of Postnatal Rats |
Kim, Min-Ju
(Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University)
Jun, Yun-Jeong (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) Yu, Hong-Il (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) Yang, So-Yeong (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) Oh, Won-Man (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) Kim, Sun-Hun (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) Kim, Min-Seok (Dental Science Research Institute, 2nd Stage Brain Korea, School of Dentistry, Chonnam National University) |
1 | Wise GE, Lin F. The molecular biology of initiation of tooth eruption. J Dent Res. 1995; 74(1):303-6. DOI ScienceOn |
2 | Wise GE, Huang H, Que BG. Gene expression of potential tooth eruption molecules in the dental follicle of the mouse. Eur J Oral Sci. 1999;107(6):482-6. DOI ScienceOn |
3 | Wise GE, Yao S, Zhang Q, Ren Y. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. Arch Oral Biol. 2002a;47(3):247-54. DOI ScienceOn |
4 | Wise GE, Frazier-Bowers S, D'Souza RN. Cellular, molecular, and genetic determinants of tooth eruption. Crit Rev Oral Biol Med. 2002b;13(4):323-34. DOI ScienceOn |
5 | Wise GE, Yao S. Expression of vascular endothelial growth factor in the dental follicle. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):173-80. DOI ScienceOn |
6 | Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95(7):3597-602. DOI ScienceOn |
7 | Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19. DOI ScienceOn |
8 | Shin JY, Baek DH, Han SB. The Effects of Sex Hormones on the Expression of ODF/OPG in Human Gingival Fibroblast and Periodontal Ligament Cell at Serum Concentration During Pregnancy. Int J Oral Biol. 2005;30(3):105-110. |
9 | Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20(3):345-57. DOI ScienceOn |
10 | Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997; 2(6):869-79. |
11 | Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996;137(6):2324-33. DOI ScienceOn |
12 | Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961-78. DOI |
13 | Roodman GD. Advances in bone biology: the osteoclast. End Rev. 1996;17:308-22. |
14 | Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-10. DOI ScienceOn |
15 | Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292-9. DOI ScienceOn |
16 | Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91(5):2004-11. DOI ScienceOn |
17 | Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001;84(7):951-8. DOI |
18 | Papoulous S. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In Osteoporosis. pp. 1209-34. 1996. |
19 | Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11(2):150-9. |
20 | Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-74. DOI |
21 | Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60(21):6001-7. |
22 | Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-19. DOI ScienceOn |
23 | Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15(1):2-12. DOI ScienceOn |
24 | Jeong HJ, Yushun T, Kim BH, Nam MY, Lee HA, Yoo YJ, Seo JT, Shin DM, Ohk SH, Lee SI. Hypertonicity Down-regulates the 1,25(OH)2Vitamin D3-induced Osteoclastogenesis Via the Modulation of RANKL Expression in Osteoblast. Int J Oral Biol. 2005;30(1);23-30. |
25 | Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem. 1998;68(2):186-94. DOI ScienceOn |
26 | Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest. 1998;101(9):1942-50. DOI ScienceOn |
27 | Kawata T, Tenjou K, Tokimasa C, Fujita T, Kaku M, Matsuki A, Kohno S, Tsutsui K, Ohtani J, Motokawa M, Shigekawa M, Tohma Y, Tanne K. Effect of alendronate on osteoclast differentiation and bone volume in transplanted bone. Exp Anim. 2004;53(1):47-51. DOI ScienceOn |
28 | Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med. 2002; 34(2):145-51. DOI ScienceOn |
29 | Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165-76. DOI ScienceOn |
30 | Fleisch H. Bisphosphonates in bone disease: From the laboratory to the patient 3rd Ed. 1997. |
31 | Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in longterm cultures of human bone marrow. J Clin Invest. 1989;83(6):1930-5. DOI |